Codexis, Inc. (NASDAQ:CDXS) Shares Sold by Paradigm Capital Management Inc. NY

Paradigm Capital Management Inc. NY lowered its stake in Codexis, Inc. (NASDAQ:CDXS) by 50.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,000 shares of the biotechnology company’s stock after selling 50,000 shares during the quarter. Paradigm Capital Management Inc. NY owned about 0.06% of Codexis worth $238,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Wolverine Trading LLC purchased a new stake in shares of Codexis in the 4th quarter valued at approximately $56,000. Two Sigma Investments LP increased its holdings in Codexis by 2.5% in the 4th quarter. Two Sigma Investments LP now owns 263,218 shares of the biotechnology company’s stock valued at $1,256,000 after purchasing an additional 6,397 shares during the last quarter. ProShare Advisors LLC raised its position in Codexis by 101.1% in the fourth quarter. ProShare Advisors LLC now owns 26,543 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 13,344 shares during the period. Nuveen Asset Management LLC raised its position in Codexis by 18.6% in the fourth quarter. Nuveen Asset Management LLC now owns 1,812,345 shares of the biotechnology company’s stock valued at $8,645,000 after purchasing an additional 283,760 shares during the period. Finally, Numerai GP LLC acquired a new position in Codexis during the fourth quarter worth $260,000. Institutional investors and hedge funds own 78.54% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Codexis to a “sell” rating in a research note on Friday.

Codexis Trading Down 1.6%

NASDAQ CDXS opened at $2.43 on Tuesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21. The firm has a market cap of $201.31 million, a price-to-earnings ratio of -2.79 and a beta of 2.56. The firm has a 50 day simple moving average of $2.43 and a 200-day simple moving average of $3.73. Codexis, Inc. has a one year low of $1.90 and a one year high of $6.08.

Codexis (NASDAQ:CDXS) last released its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). The business had revenue of $7.54 million for the quarter, compared to analyst estimates of $10.38 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. Equities research analysts anticipate that Codexis, Inc. will post -0.77 EPS for the current fiscal year.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.